Fennec Pharmaceuticals Inc (FENC): Price-to-Revenue Ratio

Brandmark of Fennec (FENC)

The implementation of software robots for processing trial data optimizes Fennec Pharmaceuticals (FENC) processes, which is reflected in the price action. The price-to-sales ratio demonstrates a current trend where 5.80 becomes the new value of the indicator. Pedmark's monopoly guarantees high margins and cash flow, while the focus on protecting children's hearing creates a sustainable market niche for this vital treatment.

FENC Fennec Pharmaceuticals P/S Multiple (04/09/2023 - 11/13/2026)

Fennec Pharmaceuticals Inc (FENC) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price fennecpharma.com|FENC - Price Target Chart
- stock exchange capitalization data:
Market Value Fennec Pharmaceuticals Inc|FENC - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Fennec Pharmaceuticals|FENC - Book Capitalization|Market Value to Equity Ratio fennecpharma.com|FENC - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Fennec Pharmaceuticals|FENC - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Fennec|FENC - Company Total Debt|Debt to Book Capital Fennec Pharmaceuticals Inc|FENC - Company Long-Term Debts|Company Short-Term Loans and Borrowings Fennec Pharmaceuticals|Immediate Liquidity fennecpharma.com
- earnings and multiples data:
FENC - Company Net Income|Expected Net Income Fennec Pharmaceuticals|FENC - P/E Multiple|Forward P/E Multiple Fennec Pharma|FENC - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Fennec Pharmaceuticals Inc|FENC - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Fennec Pharmaceuticals|FENC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share trend for the last twelve months fennecpharma.com|FENC - Earnings growth in current year|Expected net earnings per share growth next year Fennec Pharmaceuticals
- issuer revenue and sales details:
FENC - Company Revenue|Company Revenue Forecast fennecpharma.com|FENC - Price-to-Revenue Ratio|Market Cap to Projected Revenue Fennec Pharmaceuticals Inc
Summary company analytics:fennecpharma.com
Mass-produced product of Fennec

The multiple correlates market capitalization with annual revenue, reflecting investors' willingness to pay a premium per unit of sales as operating metrics shift. In the case of Fennec Pharmaceuticals (FENC), the high valuation is justified by its monopoly position and the patent protection of a unique drug, rendering the P/S ratio a tool for analyzing the premium attributed to a lack of treatment alternatives and visualizing the balance of risks on the chart.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab Biopharma IMAB|Market Cap to Revenue HRTX|Price to Sales Nuvectis Pharma Inc. NVCT|Market Cap to Revenue CHRS (Coherus)|CRBP (Corbus Pharmaceuticals, Inc.) - Market Capitalization-to-Revenue Ratio|Cardiff Oncology - Market Cap to Revenue|Market Cap to Sales Volume BYSI (beyondspringpharma.com)|BioAtla Corp - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: P/S Multiple|Price to Sales Cellectar Corp (CLRB)|Price-to-Revenue Ratio BioLineRx Ltd.|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|GTHX: P/S Multiple|Price-to-Sales Ratio KRON (Kronos Bio Inc)|KTRA (Kintara) - P/S Multiple|Price to Sales Oncternal Corp ONCT|Price-to-Revenue Ratio Portage Biotech Inc. (PRTG)